muraglitazar
Small moleculeexperimental
Muraglitazar is a dual peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ. — Wikipedia
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
8
Phase 3
10
Phase 4
0
Earliest trial started Apr 1, 2002 (NCT00245388)
Timeline
Indications
Mechanism of action
PPARA agonist
Discontinueddue to safety concerns
PPARG agonist
Discontinueddue to safety concerns
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1- Mol. weight
- 516.55 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMuraglitazar ↗
- ChEMBLCHEMBL186179 ↗
Also known as
- 2-((4-methoxyphenoxy)carbonyl-((4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)methyl)amino)acetic acid
- bms298585
- bms 298585
- bms-298585
- bms-298585
- bms-298585
- mk0478
- muraglitazar
- muraglitazar
- muraglitazar
- muraglitazar
- n-((4-methoxyphenoxy)carbonyl)-n-((4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl)methyl)glycine
- pargluva
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00130806 | Phase 3 | Sep 1, 2005 | Bristol-Myers Squibb, Merck |
| NCT00106808 | Phase 3 | Aug 1, 2005 | Bristol-Myers Squibb, Merck |
| NCT00094991 | Phase 3 | May 1, 2004 | Bristol-Myers Squibb, Merck |
| NCT00095030 | Phase 3 | Feb 1, 2004 | Bristol-Myers Squibb, Merck |
| NCT00240370 | Phase 3 | Oct 1, 2003 | Bristol-Myers Squibb |
| NCT00162175 | Phase 3 | Jul 1, 2003 | Bristol-Myers Squibb |
| NCT00246987 | Phase 3 | Jun 1, 2003 | Bristol-Myers Squibb |
| NCT00162240 | Phase 3 | Jun 1, 2003 | Bristol-Myers Squibb |
| NCT00240383 | Phase 2/Phase 3 (Phase 3) | May 1, 2002 | Bristol-Myers Squibb |
| NCT00245388 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2002 | Bristol-Myers Squibb |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 10 | 9 | 1 | 2002 |
| Merck | For profit | 4 | 1 | 1 | 2004 |
2 organizations
Page 1 / 1